Criteria Bio Ventures

To add a bio or update investment portfolio, please click update information.

Investment Portfolio

NRG Therapeutics lands £50m Series B led by SV Health Investors to advance neurodegenerative disease therapies

8 Sept 2025

NRG Therapeutics lands £50m Series B led by SV Health Investors to advance neurodegenerative disease therapies

NRG Therapeutics develops oral small-molecule drugs targeting mitochondrial dysfunction, aiming to slow or halt neurodegenerative diseases such as ALS and Parkinson’s through disease-modifying treatments.

Criteria Bio Ventures

- Life Sciences
1(12 months)
criteriabioventures.com
Update Information

More venture news

18 Feb 2026
FYLD secures a £30m Series B led by Energy Impact Partners to monitor high-risk infrastructure fieldwork with intelligence platform
Series BIndustrial
Lawhive
5 Feb 2026
Lawhive raises £45m Series B led by angel Mitch Rales to speed up legal services for consumers with AI
Series BLegal
Tem
10 Feb 2026
Tem lands £55m Series B led by Lightspeed Venture Partners to fix the energy market with transaction infrastructure
Series BEnergy

Criteria Bio Ventures

Investment Portfolio

NRG Therapeutics lands £50m Series B led by SV Health Investors to advance neurodegenerative disease therapies

More venture news

FYLD secures a £30m Series B led by Energy Impact Partners to monitor high-risk infrastructure fieldwork with intelligence platform

Lawhive raises £45m Series B led by angel Mitch Rales to speed up legal services for consumers with AI

Tem lands £55m Series B led by Lightspeed Venture Partners to fix the energy market with transaction infrastructure